Introduction
============

A key strategy in the primary prevention of cardiovascular disease (CVD) is the use of risk prediction algorithms to target preventive interventions on people who should benefit from them most.[@ehy653-B1]^,^[@ehy653-B2] There is, however, debate about the optimum algorithm for CVD risk estimation. The 2013 guidelines of the American College of Cardiology/American Heart Association (ACC/AHA)[@ehy653-B3]^,^[@ehy653-B4] have recommended the Pooled cohort equations (PCE). By contrast, the 2016 guidelines of the European Society of Cardiology[@ehy653-B5] have recommended the Systematic COronary Risk Evaluation (SCORE) algorithm.[@ehy653-B6]^,^[@ehy653-B7] The Framingham risk score (FRS)[@ehy653-B8] and the Reynolds risk score (RRS)[@ehy653-B9]^,^[@ehy653-B10] have been recommended by other North American guidelines.[@ehy653-B11]^,^[@ehy653-B12] Additional algorithms have been recommended by further guidelines.[@ehy653-B13]^,^[@ehy653-B14]

Such contrasting recommendations may create confusion among practitioners, potentially reflecting uncertainty about the performance of different algorithms under different circumstances. For example, because CVD event rates and average risk factor levels vary over time and place, algorithms developed in one population may not predict the correct risk in the target population being screened (i.e. they may not be well 'calibrated'[@ehy653-B15]^,^[@ehy653-B16]). Furthermore, although most CVD risk algorithms include information on a common set of risk factors, algorithms can differ owing to differences in the exact set of risk factors included, mathematical formulations used, and definitions of CVD outcomes employed. Hence, use of different algorithms as currently recommended could lead to varying clinical performance and uneven efficiency in allocating preventive interventions. Only few and relatively small studies have, however, provided head-to-head comparisons of different risk prediction algorithms recommend by primary prevention guidelines for allocation of statin therapy.[@ehy653-B17] Despite some previous attempts to adjust risk algorithms to local and/or contemporary circumstances (i.e. 'recalibration'),[@ehy653-B17]^,^[@ehy653-B20] few have compared recalibrated versions of algorithms systematically across many populations.

Our study, therefore, aimed to address two sets of questions. First, how do risk prediction algorithms differ in term of predictive accuracy and clinical performance when evaluated in the same population? We chose algorithms that have been recommended by a guideline statement and could be evaluated with the information available in our consortium dataset. Hence, we conducted head-to-head comparisons of original versions of four risk algorithms (FRS, SCORE, PCE, and RRS), evaluating them using measures of predictive accuracy (e.g. discrimination, calibration) as well as clinical performance (e.g. we modelled the potential impact of initiating statin therapy as recommended by primary prevention CVD guidelines[@ehy653-B3]^,^[@ehy653-B4]). The second set of questions is: what is the clinical impact of adjusting these algorithms to local and contemporary circumstances, and how do they then compare to each other? To address them, we recalibrated these algorithms using CVD event rates and risk factor values of the target populations, and compared the performance of the original and recalibrated versions of algorithms across multiple settings.

Methods
=======

Data sources
------------

We analysed data from the Emerging Risk Factors Collaboration (ERFC), a consortium of prospective cohort studies with information on a variety of risk factors.[@ehy653-B21] Prospective cohort studies were included in this analysis if they met all the following criteria: (i) had not contributed data to the development of any of the risk prediction algorithms studied in this analysis[@ehy653-B4]^,^[@ehy653-B6]^,^[@ehy653-B8]; (ii) had recorded information on risk factors necessary to calculate algorithms \[i.e. age, sex, smoking status, history of diabetes, systolic blood pressure, total and high-density lipoprotein cholesterol, ethnicity, and use of antihypertensive medications; [Supplementary material online](#sup1){ref-type="supplementary-material"}, *[Table S1](#sup1){ref-type="supplementary-material"}* and [Supplementary material online](#sup1){ref-type="supplementary-material"}, *Appendix S1*\]; (iii) were approximately population based (i.e. did not select participants on the basis of having previous disease); (iv) had recorded cause-specific deaths and non-fatal CVD events \[i.e. non-fatal myocardial infarction (MI) or stroke\] using well-defined criteria; and (v) had at least 1 year of follow-up after baseline. Details of contributing studies are in [Supplementary material online](#sup1){ref-type="supplementary-material"}, *[Table S2](#sup1){ref-type="supplementary-material"}* and [Supplementary material online](#sup1){ref-type="supplementary-material"}, *Appendix S2*. All studies used definitions of non-fatal MI based on World Health Organization (or similar) criteria and of non-fatal stroke based on clinical and brain imaging features. In registering fatal outcomes, all contributing studies classified deaths according to the primary cause (or, in its absence, the underlying cause), and used *International Classification of Diseases*, revisions 8, 9, and 10, coding to at least three digits. Ascertainment of fatal outcomes was based on death certificates, with 56 studies also involving review of medical records, autopsy findings, and other supplementary sources. [Supplementary material online](#sup1){ref-type="supplementary-material"}, *[Table S3](#sup1){ref-type="supplementary-material"}* provides International Classification of Diseases (ICD) codes used to define outcomes used in each CVD risk prediction algorithm.

Statistical analysis
--------------------

Analyses included participants aged between 40 and 79 years, excluding those with a known history of CVD at baseline \[i.e. coronary heart disease (CHD), other heart disease, stroke, transient ischaemic attack, peripheral vascular disease, atrial fibrillation, heart failure, or any cardiovascular surgery\], as defined by each study.[@ehy653-B21]^,^[@ehy653-B22] For each participant, we used original versions of FRS, SCORE, PCE, and RRS to calculate the predicted 10 year risk of CVD events ([Supplementary material online](#sup1){ref-type="supplementary-material"}, *Appendix S1*). To enable comparison with the three other risk prediction algorithms evaluated in this study, we used a rescaled version of the FRS algorithm which predicts non-fatal MI, fatal CHD, or any stroke (rather than the broader CVD outcome it was originally derived for).[@ehy653-B8] For SCORE, we used relevant high or low-risk versions depending on the geographical location of the cohort as recommended by the ESC guidelines.[@ehy653-B5] Analyses involving RRS were performed in a subset of participants who had information available on C-reactive protein, family history of premature MI, and HbA1c (if female and with diabetes) ([Supplementary material online](#sup1){ref-type="supplementary-material"}, *[Table S1](#sup1){ref-type="supplementary-material"}*).

To help provide systematic evaluation of the four risk algorithms to predict relevant CVD endpoints, we used the following outcome definitions. The principal outcome was the composite of CVD events during the initial 10 year period of follow-up as defined by each algorithm ('the algorithm-specific outcome'): first onset of non-fatal MI, fatal CHD, or any stroke for FRS and PCE; non-fatal MI, fatal CHD or any stroke, coronary revascularization, or any CVD death for RRS; fatal CVD for SCORE ([Supplementary material online](#sup1){ref-type="supplementary-material"}, *[Table S3](#sup1){ref-type="supplementary-material"}*). The secondary outcome was a 'common' CVD outcome, defined as the composite of non-fatal MI, fatal CHD, or any stroke, adopting the definition of the 2013 ACC/AHA guidelines (and used by PCE and FRS).[@ehy653-B4] Outcomes were censored if a participant was lost to follow-up, died from non-CVD causes, or reached 10 years of follow-up. Participants contributed only the first non-fatal or fatal CVD outcome (i.e. deaths preceded by non-fatal CVD events were not included) except in the case of the SCORE-specific outcome, for which all fatal CVD events were included.

We assessed risk discrimination using the C-index which estimates the probability of correctly predicting who will have a CVD event first in a randomly selected pair of participants.[@ehy653-B23] The C-index calculation was stratified by sex and involved a two-stage approach, with estimates calculated separately within each study before pooling across studies weighting by the number of contributing events.[@ehy653-B24] We assessed calibration of risk algorithms for each algorithm-specific outcome by comparing predicted and observed risks calculated for groups of participants defined by 5 year age categories and calculating goodness of fit tests.[@ehy653-B25][Supplementary material online](#sup1){ref-type="supplementary-material"}, *Appendix S3* provides further details of the methods used to assess calibration. We recalibrated each algorithm as shown in [Supplementary material online](#sup1){ref-type="supplementary-material"}, *[Figure S1](#sup1){ref-type="supplementary-material"}* and [Supplementary material online](#sup1){ref-type="supplementary-material"}, *Appendix S3*. Our approach involved adaptation of original risk algorithms using the risk factor profile and CVD incidence of target populations. Recalibration to CVD incidence involved two approaches. First, we recalibrated each algorithm to predict incidence of the endpoint it was derived to predict (the algorithm-specific outcome). Second, to enable head-to-head comparisons, we recalibrated SCORE and RRS to the common CVD outcome used by FRS and PCE, as mentioned above. Only studies with at least 10 years of follow-up were used in analyses involving recalibration, or assessment of calibration.

To assess the clinical implications of using different algorithms to initiate statin therapy in those whose 10 year CVD risk exceeds a given threshold (as recommended by several CVD primary prevention guideline statements[@ehy653-B1]^,^[@ehy653-B3]^,^[@ehy653-B12]), we estimated the number of individuals who would be eligible for treatment and the potential cases avoided. First, we assumed CVD risk assessment for a population of 100 000 men and women aged ≥40 years without CVD at baseline and not already taking statins or meeting guideline recommendations for statin treatment (i.e. people without a history of diabetes or CVD and with low-density lipoprotein (LDL) cholesterol \<190 mg/dL).[@ehy653-B3] Second, we assumed the same age structure of a standard population of the United States. Third, we assumed age- and sex-specific incidence rates for CVD events as in the current study. Fourth, we assumed statin allocation according to the threshold of predicted 10 year CVD risk recommended by 2013 ACC/AHA guidelines[@ehy653-B4] for first-onset fatal and non-fatal CVD events (i.e. ≥7.5%), or by the 2016 ESC Guidelines for fatal CVD (i.e. ≥5%).[@ehy653-B5] Fifth, we assumed CVD risk reductions of 20% with statin treatment in people without a history of CVD, as reported by the Cholesterol Treatment Trialists' Collaboration.[@ehy653-B26] We also compared categorization of participants across different algorithms before and after their recalibration using the net reclassification improvement (NRI).[@ehy653-B27]

Analyses were performed using Stata version 14. *P*-values are two-sided. The study was designed and conducted by this collaboration's academic coordinating centre, and was approved by the Cambridgeshire Ethics Review Committee. The funders had no scientific role in the study.

Results
=======

We analysed data on 360 737 participants without prior CVD who were recruited into 86 prospective cohorts between the years 1963 and 2003 ([Supplementary material online](#sup1){ref-type="supplementary-material"}, *[Table S2](#sup1){ref-type="supplementary-material"}*). The mean (standard deviation) age at baseline was 59 (8) years; 53% were male. Sixty-nine percent of the participants were recruited in European countries, 18% in North America, and the remainder mostly in Japan and Australia. Median (5^th^--95^th^ percentile) follow-up was 10.2 (3.4--21.3) years, and during the initial 10 years of follow-up (3.1 million person-years at risk), 14 564 incident CVD events were recorded according to our common and FRS/PCE CVD definition, including 9259 CHD events and 5305 stroke events. At baseline, the median (5^th^--95^th^ percentile) predicted 10 year CVD risks were 5.54% (1.02--23.34%) using FRS, 2.49% (0.13--23.25%) using SCORE, and 6.43% (0.69--33.33%) using PCE (*Table [1](#ehy653-T1){ref-type="table"}*). Baseline characteristics for the subset of participants with information on the RRS are presented in [Supplementary material online](#sup1){ref-type="supplementary-material"}, *[Table S4](#sup1){ref-type="supplementary-material"}*. Table 1Baseline characteristics and predicted 10 year cardiovascular disease risk relevant to assessed algorithmsBaseline characteristicMean (SD) or *n* (%)Age at survey (years)59 (8.0)Males189 342 (52.5%)Current smoking98 593 (27.3%)History of diabetes16 758 (4.6%)Systolic blood pressure (mmHg)132 (19)Total cholesterol (mmol/L)5.83 (1.08)HDL cholesterol (mmol/L)1.33 (0.38)Total/HDL cholesterol ratio4.50 (1.61)Hypertension medication37 960 (10.5)Lipid lowering medication7929 (5.1)**Predicted 10 year risk (%)median (5^th^--95^th^ percentiles)** Framingham risk score (FRS)5.54% (1.02--23.34) Systematic COronary Risk Evaluation (SCORE)2.49% (0.13--23.25) Pooled cohort equations (PCE)6.43% (0.69--33.33)[^3][^4]

Discrimination and calibration
------------------------------

When using algorithm-specific CVD outcomes, each algorithm provided broadly similar discrimination, with absolute C-index values ranging from 0.7010 to 0.7605. The pooled cohort equations provided somewhat greater risk discrimination than FRS or SCORE for all algorithm-specific outcomes, with differences in overall C-index compared with FRS between 0.0039 and 0.0131 (*P* \< 0.001 when testing the null hypothesis of no difference between C-indices; *Figure [1](#ehy653-F1){ref-type="fig"}*). Differences were greater for women than men, but similar among participants from European and North American cohorts ([Supplementary material online](#sup1){ref-type="supplementary-material"}, *[Figure S2](#sup1){ref-type="supplementary-material"}*). A similar pattern was observed in analyses restricted to participants with complete data enabling calculation of RRS ([Supplementary material online](#sup1){ref-type="supplementary-material"}, *[Figure S3](#sup1){ref-type="supplementary-material"}*). Differences in the C-index among algorithms were not affected by study recruitment periods ([Supplementary material online](#sup1){ref-type="supplementary-material"}, *[Figure S4](#sup1){ref-type="supplementary-material"}*).

![Discrimination abilities of original versions of three risk prediction algorithms compared with the Framingham risk score using alternative CVD definitions. Number of events observed according to CVD definitions used by the Pooled Cohort Equations, the Systematic COronary Risk Evaluation and the Reynolds Risk Score respectively were 14 564, 7433 and 17 642. Equivalent event numbers in the subset of participants with complete data for estimation of the Reynolds Risk Score were 6670, 2966 and 7953 respectively. FRS, Framingham risk score; PCE, pooled cohort equations; RRS, Reynolds risk score; SCORE, Systematic COronary Risk Evaluation. \**P* \< 0.05; \*\**P* \< 0.001.](ehy653f1){#ehy653-F1}

For each algorithm-specific outcome, on average across cohorts the predicted 10 year risk was 1.10 times observed risk for FRS, 1.52 for SCORE, 1.41 for PCE, and 0.90 for RRS (*P* \< 0.0001 for goodness of fit/calibration for all algorithms; *Figure [2](#ehy653-F2){ref-type="fig"}* and [Supplementary material online](#sup1){ref-type="supplementary-material"}, *Figures S5* and *S6*). On average the extent of relative mis-calibration was similar in men and women, and across all ages for SCORE and PCE ([Supplementary material online](#sup1){ref-type="supplementary-material"}, *[Figure S5](#sup1){ref-type="supplementary-material"}*) which translated to greater discrepancy between absolute predicted and observed risks at older ages when using these algorithms ([Supplementary material online](#sup1){ref-type="supplementary-material"}, *[Figure S6](#sup1){ref-type="supplementary-material"}*). Framingham risk score tended to over-predict in men and younger women but to under-predict in older women. Reynolds risk score underestimated risk somewhat in men, but on average was well calibrated in women (*Figure [2](#ehy653-F2){ref-type="fig"}*, [Supplementary material online](#sup1){ref-type="supplementary-material"}, *Figures S5* and *S6*). The extent and direction of mis-calibration varied substantially across individual cohorts, ranging from more than 50% underestimation to \>400% overestimation of risk ([Supplementary material online](#sup1){ref-type="supplementary-material"}, *Figures S7* and *S8*). Heterogeneity in calibration could not be systematically explained by broad geographical region but was partially explained by year of baseline screening ([Supplementary material online](#sup1){ref-type="supplementary-material"}, *[Figure S9](#sup1){ref-type="supplementary-material"}*). After recalibration of algorithms to the incidence of the common CVD outcome and risk factor distribution of the cohorts contributing to the current analysis, the distribution of predicted 10 year CVD risk was similar across the four algorithms we studied ([Supplementary material online](#sup1){ref-type="supplementary-material"}, *[Figure S10](#sup1){ref-type="supplementary-material"}*), yielding good calibration for each algorithm ([Supplementary material online](#sup1){ref-type="supplementary-material"}, *[Figure S11](#sup1){ref-type="supplementary-material"}*). Risk discrimination did not change with recalibration since ranking of participant risk is unaffected by the recalibration methods used ([Supplementary material online](#sup1){ref-type="supplementary-material"}, *[Figure S1](#sup1){ref-type="supplementary-material"}* and *Appendix S3*).

![Observed and predicted 10-year cardiovascular risk using original version of prediction algorithms. Points presented in each plot are for each 5-year age group between 40--44 to 75--79 years. Observed risk was calculated according to the CVD definition specific to each algorithm. Assessment of the Framingham Risk Score, the Systematic COronary Risk Evaluation and the Pooled Cohort Equations was based on 223 663 participants from 47 cohorts with at least 10 years of follow-up. Assessment of the Reynolds Risk Score was based on 91 008 participants from 27 cohorts with at least 10 years of follow-up. FRS, Framingham risk score; PCE, pooled cohort equations; RRS, Reynolds risk score; SCORE, Systematic COronary Risk Evaluation.](ehy653f2){#ehy653-F2}

Estimates of clinical performance
---------------------------------

We initially conducted modelling that: employed original versions of the four CVD risk algorithms we studied; was weighted to represent the age and sex distribution of a standard US population ≥40 years; focused on individuals not already taking or eligible for statin treatment (i.e. people without a history of diabetes or CVD and with LDL \<190 mg/dL)[@ehy653-B3]; and defined the threshold for initiation of statin treatment as an absolute 10 year risk of ≥7.5% for FRS, PCE, and RRS, and ≥5% for SCORE ('high risk').

Under this scenario, we estimated that the proportion of individuals classified as high-risk (i.e. eligible for statin treatment) was 32% with FRS, 29% with SCORE, 39% with PCE, and 32% with RRS ([Supplementary material online](#sup1){ref-type="supplementary-material"}, *[Table S5](#sup1){ref-type="supplementary-material"}* and *Figure [3](#ehy653-F3){ref-type="fig"}*). By contrast, after recalibration (using algorithmic-specific CVD endpoints), FRS, SCORE, PCE, and RRS predicted CVD outcomes more accurately, classified lower proportions of people as high risk, and identified higher proportions of CVD events among people classified as high risk. After further recalibration to the common CVD endpoint, the proportion of individuals classified as high risk lowered to a near uniform level (22%, 22%, 24%, and 23% with FRS, SCORE, PCE, and RRS, respectively). Of those classified as high risk by the original versions of algorithms, 11% later developed a first CVD event within 10 years (i.e. the positive predictive value was 11%, 11%, 10%, and 11%, respectively). By contrast, it was 13% with the recalibrated algorithms ([Supplementary material online](#sup1){ref-type="supplementary-material"}, *[Table S5](#sup1){ref-type="supplementary-material"}*).

![Estimated public health impact with screening using original and recalibrated cardiovascular disease risk prediction algorithms over a range of risk thresholds in a standard US population of 100 000 people aged over 40 years. Cardiovascular disease includes fatal coronary heart disease, fatal, and non-fatal myocardial infarction and any stroke. FRS, Framingham risk score; PCE, pooled cohort equations; RRS, Reynolds risk score; SCORE, Systematic COronary Risk Evaluation.](ehy653f3){#ehy653-F3}

Based on these estimates, we calculated that to prevent one CVD event when using original versions of FRS, SCORE, PCE, or RRS it would be necessary to initiate statin therapy in 46, 44, 51, or 45 individuals, respectively (following screening of 145, 150, 131, or 142 individuals, respectively; *Figure [3](#ehy653-F3){ref-type="fig"}* and [Supplementary material online](#sup1){ref-type="supplementary-material"}, *[Table S5](#sup1){ref-type="supplementary-material"}*). By contrast, when using any of the recalibrated algorithms, one CVD event could be prevented by initiating statin therapy in 38 participants (following screening of 174, 171, 160, or 165 individuals, respectively). Similar findings to those observed above were noted in analyses that used a range of treatment thresholds different from those in current guidelines (*Figure [3](#ehy653-F3){ref-type="fig"}*) with the divergent clinical performance of original algorithms converging to become almost identical at any treatment threshold after recalibration to a common CVD endpoint.

We then modelled the concordance of statin treatment decisions based on use of these algorithms. Before recalibration, 41% of all individuals were at high risk with at least one of the four algorithms and 58% of these (24% of all individuals) were at high risk with all four. By contrast, after recalibration to our common CVD outcome, 28% of individuals were at high risk with at least one algorithm and 63% of these (18% of all individuals) were at high risk with all four ([Supplementary material online](#sup1){ref-type="supplementary-material"}, *[Figure S12](#sup1){ref-type="supplementary-material"}*). Discordance in treatment decisions before recalibration tended to be greatest when comparing SCORE to the other algorithms (*Figure [4](#ehy653-F4){ref-type="fig"}*). For example, in pairwise comparisons between FRS and SCORE, in every 100 000 people screened 36 794 would be classified as high risk with either FRS or SCORE and 24 157 (66% of these) would be classified as high risk with both FRS and SCORE. By contrast, after recalibration, 18 716 (76%) of the 24 708 individuals at high risk with either FRS or SCORE would be at high risk with both algorithms (*Figure [4](#ehy653-F4){ref-type="fig"}*). This greater concordance between algorithms in identifying those at high risk was also illustrated by a decrease in the NRI among both cases and event-free participants after recalibration ([Supplementary material online](#sup1){ref-type="supplementary-material"}, *[Table S6](#sup1){ref-type="supplementary-material"}*) and greater agreement between the absolute risk predictions ([Supplementary material online](#sup1){ref-type="supplementary-material"}, *[Figure S13](#sup1){ref-type="supplementary-material"}*).

![Pairwise overlap in those classified at high risk when applying CVD risk prediction algorithms to a US standard population of 100 000 individuals. Risk thresholds to define high risk were set at 7.5% for Framingham risk score, pooled cohort equations and Reynolds risk score and 5% for Systematic COronary Risk Evaluation before recalibration. After to recalibration to our common CVD endpoint a risk threshold of 7.5% was used for all algorithms. *n* represents the number of individuals classified at high risk with either algorithm. FRS, Framingham risk score; PCE, pooled cohort equations; RRS, Reynolds risk score; SCORE, Systematic COronary Risk Evaluation.](ehy653f4){#ehy653-F4}

Discussion
==========

In an analysis of individual-participant data on over 350 000 people without a history of CVD at baseline, we systematically evaluated several risk algorithms recommended by North American and European guidelines for primary prevention of CVD. Our study's main finding was that the clinical performance of four widely used risk algorithms varied substantially, predominantly due to differing extent of calibration. By contrast, we observed only slight differences among the algorithms in relation to risk discrimination (a measure of predictive accuracy that is not influenced by the extent of model calibration). After recalibration, however, the performance of the four algorithms was essentially equalized. Our modelling suggested, therefore, that targeting of CVD preventive action to clinical need would improve considerably due to higher accuracy of individual risk predictions. A key implication of these results is that CVD primary prevention guidelines should shift away from debates about the relative merits of particular risk algorithms and, instead, achieve consensus about the need for more widespread use of *any* recalibrated algorithm.

Our findings have suggested that effective recalibration can be achieved through the use of simple methods that can be applied using aggregate level data on CVD event rates and average risk factor values for a target population to be screened. To scale this approach for clinical and public health purposes, cardiovascular bodies might facilitate the collation and regular updating of national and regional age- and sex-specific CVD event rates and risk factor data, including for particular geographical areas and ethnic groups with distinctive CVD event rates and risk factors values. This information could then be embedded in user-friendly risk prediction tools (e.g. online risk calculators or electronic health records systems), enabling regular and simple recalibration, as previously described.[@ehy653-B28]^,^[@ehy653-B29] An alternative approach is the periodic development of new risk algorithms, although it would be more costly and time-consuming than recalibration because it entails launch of large new cohort studies and their long-term follow-up.

In contrast with previous analyses of simulated data, studies in single populations, or comparisons of risk scores without recalibration,[@ehy653-B17]^,^[@ehy653-B30] our study directly compared original and recalibrated versions of four algorithms used across many different populations, providing the first demonstration of the extent of CVD risk prediction improvement achievable through recalibration. For example, following recalibration we observed that the proportion of individuals classified as high risk reduced from about 40% to 23%, and the number of individuals needed to initiate statin therapy to prevent one event reduced from between 44--51 to around 38. However, our modelling reflects the average improvement that can be achieved by recalibration across a set of different populations in which the initial extent and direction of mis-calibration varied substantially, partly due to differences in baseline study year. Therefore, the clinical improvement that could be achieved in countries or regions where mis-calibration is more extreme could potentially be much greater.

Our approach to recalibration was distinctive in two ways. First, it extended previous recalibration methods[@ehy653-B36] by using age groups instead of categories of predicted risk, which allows direct application to population data that are routinely recorded. Second, it differed from other recalibration methods proposed for specific CVD risk algorithms[@ehy653-B28]^,^[@ehy653-B29] by providing a simpler procedure applicable to algorithms derived using any type of statistical model. Because we studied participant-level data from cohorts with prolonged follow-up, we could adopt a uniform approach to statistical analyses and conduct time-to-event analyses. To avoid providing over-optimistic assessment of algorithm performance, we omitted cohorts that had previously contributed data to the derivation of the risk algorithms we studied. Our clinical modelling was robust to different scenarios. The generalizability of our findings was enhanced by inclusion of several dozen population cohorts in 22 countries, mostly in Europe and North America, and the broad range in baseline year of recruitment across studies.

Our study had potential limitations. Because we used data from the target cohorts themselves to recalibrate algorithms, the benefits of recalibration could have been exaggerated (albeit in a manner that would have affected each algorithm identically). Conversely, inaccuracy in CVD ascertainment in contributing cohorts would tend to worsen the apparent performance of algorithms (again, affecting each algorithm identically).[@ehy653-B37] Our modelling could have over-estimated potential benefits of statin therapy because not all people eligible for statins will receive them or be willing or able to take them. On the other hand, greater clinical impact than suggested by our modelling would be estimated if we had used less conservative assumptions (e.g. use of more efficacious statin regimens or additional treatments; longer time horizons; and lifestyle changes). We did not formally incorporate the impact of the potential hazards of statins into our modelling. We had incomplete information on medication use (such as statins and antihypertensive drugs) or cardiovascular intervention (such as coronary revascularization) during follow-up, which may have influenced our estimates of the observed CVD risk. Revascularization endpoints may have been differentially recorded across studies, which may have impacted on our assessment of calibration of the original RRS. There is, as yet, no randomized evidence that CVD risk assessment translates into CVD prevention.[@ehy653-B38]

Conclusion
==========

Whereas the performance of the original versions of four widely used CVD risk algorithms varied substantially, simple recalibration essentially equalized them and improved targeting of CVD preventive action to clinical need. This study supports the concept of using regularly recalibrated risk algorithms in routine clinical practice.
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[^1]: Lisa Pennells and Stephen Kaptoge authors contributed equally to this article.

[^2]: Investigators of the Emerging Risk Factors Collaboration are listed at the end of this manuscript.

[^3]: Data are from 86 cohorts with 360 737 participants and 23 563 CVD events (14 538 occurring within 10 years). Versions of FRS and PCE used predict risk of fatal or non-fatal CVD, SCORE predicts risk of fatal CVD.

[^4]: HDL, high-density lipoprotein.
